CA 19-9 tumor marker test can help predict early-stage pancreatic tumor patients CA 19-9 tumor marker test especially very important to early-stage patients, Mayo finds Only 1 1 in 5 U.S. Pancreatic cancer sufferers receive a available widely, inexpensive blood check at diagnosis that will help predict whether they will probably have an improved or worse outcome than average and information treatment appropriately, a Mayo Clinic research shows impotens . People who test positive for elevated levels of a particular tumor marker have a tendency to do worse than others, but if they are candidates for surgery and also have chemotherapy before their operations, this personalized treatment sequence eliminates the elevated biomarker's negative effect, researchers found.
CARMAT is usually continuing to implement its strategy for providing the world’s innovative artificial heart. The development of complicated bioprotheses is one of the most promising new approaches in medication. CARMAT embodies the exploitation of analysis excellence and the convergence of several cutting-edge technologies. The business is today addressing a significant challenge in public areas health with an extremely significant socio-economic impact.. CARMAT completes assembly of 1st artificial heart clinical version Achievement of an integral milestone announced during the company’s successful IPO on NYSE Alternext in July 2010 The unit will be utilized for the first-in-man clinical trials scheduled for 2011 CARMAT , the designer and programmer of the world’s most advanced artificial center, today announced that it all has completed the assembly of the initial clinical version of it is artificial heart .